𝔖 Bobbio Scriptorium
✦   LIBER   ✦

387 - Adjuvant therapy of renal cell carcinoma (RCC) with a pure cell-lysate autologous tumorvaccine (aTm)

✍ Scribed by C. Ulbrich; R. Repmann; A.J.W. Goldschmidt; S.W. Hockertz

Book ID
117664641
Publisher
Elsevier Science
Year
1997
Tongue
English
Weight
261 KB
Volume
33
Category
Article
ISSN
0959-8049

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Autologous tumour cell vaccine may reduc
Autologous tumour cell vaccine may reduce risk of tumour progression in people with primary renal cell carcinoma: Abstracted from: Jocham D, Richter A, Hoffmann L et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet 2004;363:594–599.
✍ Chris Coppin πŸ“‚ Article πŸ“… 2004 πŸ› Elsevier Science 🌐 English βš– 234 KB
Adjuvant immunotherapy treatment of rena
Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and Bacillus Calmette-Guèrin: Five-year results of a prospective randomized study
✍ Enzo Galligioni; Michele Quaia; Alberto Merlo; Antonino Carbone; Antonella Spada πŸ“‚ Article πŸ“… 1996 πŸ› John Wiley and Sons 🌐 English βš– 613 KB

## BACKGROUND. Active specific immunotherapy (ASI) is a strategy that attempts to boost the host's immune response specifically against its own tumor. The purpose of this study was to investigate the effect of adjuvant AS1 in patients with renal carcinoma. ## METHODS. Of 120 consecutive patient